NCT01883544View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

January 31, 2014

Conditions
Healthy Subjects
Interventions
DRUG

ALXN1007

Trial Locations (1)

21225

PAREXEL Baltimore EPCU, Baltimore

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY